Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
Artemis II Moon Mission
2APR

Crew's Own Cells Fly to the Moon as Living Experiments

1 min read
11:46UTC

Organ-on-chip devices grown from each astronaut's bone marrow will produce the first personalised deep-space radiation data.

ScienceDeveloping
Key takeaway

Personalised organ-on-chip experiments will yield the first individualised deep-space radiation data.

4 organ-on-chip devices aboard Orion contain cells grown from each crew member's own bone marrow as part of the AVATAR (Virtual Astronaut Tissue Analog Response) experiment 1. Partners include BARDA, the NIH, and the Wyss Institute at Harvard. The chips are microfluidic devices that mimic human organ tissue at small scale. Exposing them to deep-space radiation alongside the crew members who donated the cells produces the first individualised dataset on how that radiation affects human biology. Previous space radiation studies relied on generic tissue samples or animal models. The data will inform dosage limits, shielding requirements, and medical protocols for longer missions. For a programme whose critics question its scientific return, these chips represent concrete research that could not be conducted anywhere closer to Earth.

Deep Analysis

In plain English

Each astronaut donated some of their bone marrow cells before the mission. Scientists grew those cells into tiny devices called organ-on-chips: microfluidic chips the size of a USB drive that mimic how human organs behave. These chips are flying alongside the crew members who donated the cells. When both are exposed to the same deep-space radiation environment, scientists can measure exactly how that radiation affects those specific people's biology, not a generic average. This matters because future missions to Mars will expose crews to far more radiation than any previous mission. Understanding individual variation in radiation tolerance could determine crew selection, mission duration, and medical protocols for those journeys.

First Reported In

Update #1 · Artemis II Commits to the Moon With Three Open Questions

Canadian Space Agency· 2 Apr 2026
Read original
Causes and effects
This Event
Crew's Own Cells Fly to the Moon as Living Experiments
These are the first biological experiments in deep space tailored to individual crew members, bridging a gap between generic radiation models and personalised medicine.
Different Perspectives
JAXA
JAXA
JAXA is an Artemis Accords signatory with the Lunar Cruiser rover planned for south-pole surface operations; Chang'e 7's first-arrival timeline compresses the window those surface systems were designed to operate in alongside American crew.
Space Research Institute RAS / Roscosmos
Space Research Institute RAS / Roscosmos
The LILEM instrument on Chang'e 7 gives Russia science-cooperation presence at Shackleton's rim with no independent crewed lunar capability on a public timeline. This is Roscosmos's only confirmed path to south-pole science in the current decade.
CNSA / China Manned Space Agency
CNSA / China Manned Space Agency
Chang'e 7 at Wenchang confirmed a second-half 2026 launch for Shackleton rim, 18 to 24 months before any American crewed arrival. The mission carries a Russian LILEM instrument, giving Roscosmos a south-pole science foothold inside China's programme.
Jeremy Hansen / Canadian Space Agency
Jeremy Hansen / Canadian Space Agency
Hansen appeared at the 16 April JSC press conference in his only public moment since splashdown. Canada's Canadarm3 remains without a confirmed deployment host after Gateway cancellation, with CSA maintaining institutional silence on the programme's status.
Airbus Defence and Space
Airbus Defence and Space
Airbus has issued no post-mission ESM performance statement; its press room returned a 404 error on a 14 April check. The only named Airbus engineer quote on the mission appeared in a Nature interview, not a company release.
Daniel Neuenschwander / European Space Agency
Daniel Neuenschwander / European Space Agency
ESA's 11 April statement praised ESM translunar injection precision and omitted the pressurisation valve anomaly; the June 2026 Council is the sole stated review forum. ESM-3 is at KSC without a corrected-baseline disclosure to justify its readiness.